Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Pneumonol Alergol Pol ; 65(5-6): 318-25, 1997.
Article in Polish | MEDLINE | ID: mdl-9340057

ABSTRACT

62 patients with a limited small cell lung cancer were randomly qualified into two groups. 32 patients of the first group were treated only with the chemotherapy regimen, consisted of three drugs (Carboplatine, Etoposide and Vincristine administered in 6 courses, on regular, 3-weeks basis). The second group of 30 patients had been treated with the identical chemotherapy schedule, but alternatively combined with a primary site irradiation in a total dose of 40Gy, applied in parts after the chemotherapy courses 2, 3, and 4. The significantly higher proportion of a complete remission results was observed in the alternate-treatment group: 14/30 (46.7%), compared with the chemotherapy-only group: 10/32 (31%). Alternate chemoradiotherapy resulted both in the increased median remission duration time, and the increased median survival time. Only in the alternate chemotherapy group, in 14/30 patients (46.7%) the pneumotoxicity symptoms appeared, whilst no differences in other organ-specific treatment-induced toxic effects were noted.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Small Cell/drug therapy , Carcinoma, Small Cell/radiotherapy , Lung Neoplasms/drug therapy , Lung Neoplasms/radiotherapy , Adult , Aged , Carboplatin/administration & dosage , Carcinoma, Small Cell/mortality , Combined Modality Therapy , Etoposide/administration & dosage , Female , Humans , Lung Neoplasms/mortality , Male , Middle Aged , Survival Rate , Vincristine/administration & dosage
2.
Acta Obstet Gynecol Scand ; 75(3): 281-6, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8607344

ABSTRACT

BACKGROUND: Due to rarity of fallopian tube cancer most series on this tumor are small and many problems have remained unsolved. The aim of this report is to review our experience with this neoplasm and to compare it with previously published data. METHODS: Retrospective study of 26 patients with fallopian tube cancer treated in one institution between 1974 and 1994. All patients underwent primary surgical treatment and 18 received adjuvant therapy including pelvic irradiation in 14 cases and chemotherapy in four. RESULTS: Relapse occurred in 18 out of 25 followed up patients. Upper abdominal component of relapse was encountered in 12 patients (67%), pelvic component - in eight (44%) and extraperitoneal component - six (33%). Pelvic relapse occurred in two out of 13 followed up patients treated with postoperative irradiation and in six out of 12 who did not receive postoperative radiotherapy. Survival ranged from 6 to 218+ months (median 23 months). Five-year actual survival was 33%. There were no 2-year survivors in patients presenting with stage II-IV disease. No correlation was found between tumor grade and survival. CONCLUSIONS: Fallopian tube cancer is a treatable disease but cure can be only achieved in patients with early tumor. Postoperative radiotherapy may result in better local control but does not preclude extrapelvic dissemination, therefore adjuvant chemotherapy should be considered in high risk patients. Registration of all new cases as well as prospective multicenter studies are warranted to establish optimal management.


Subject(s)
Fallopian Tube Neoplasms/epidemiology , Age Factors , Aged , Combined Modality Therapy , Fallopian Tube Neoplasms/mortality , Fallopian Tube Neoplasms/pathology , Fallopian Tube Neoplasms/surgery , Female , Follow-Up Studies , Humans , Middle Aged , Neoplasm Metastasis , Neoplasm Recurrence, Local/epidemiology , Neoplasm Staging , Poland/epidemiology , Survival Rate
3.
Neoplasma ; 43(2): 133-7, 1996.
Article in English | MEDLINE | ID: mdl-8843976

ABSTRACT

The objective of this study was to assess the pattern of autopsy findings in 174 small cell lung cancer patients treated between 1971 and 1991 at seven Polish medical centres. Eighty nine autopsied patients were previously treated with different chemotherapy regimens including 32 patients who also received chest irradiation, 74 received only supportive care and for 11 patients the data on treatment were not available. The age range at diagnosis was 28-81 years (median 57); there were 39 females (22%) and 135 males (78%). Seventy two patients had limited disease at the time of diagnosis, 86-extensive disease and in 16 the disease extent was not determined. The primary tumor and/or metastases in regional lymph nodes were present in 157 autopsies (90%). There was a significant difference in the rate of locoregional disease found at autopsy in patients given chemotherapy and in those who received only supportive care (85% and 100%, respectively; p = 0.01). Chest radiation therapy given in limited disease as an adjunct to chemotherapy did not decrease the rate of persistent locoregional disease (primary tumor in the chest was found in 92% of irradiated and in 96% of nonirradiated patients). Locoregional tumor deposit only was found in 28 (16%). Distant metastases were distributed in 143 patients (82%) and were found in 25 different locations, most frequently in liver (49%), suprarenal glands (25%), peripheral lymph nodes (21%), kidneys (18%), brain (17%) and pancreas (12%). In 3 patients no tumor foci were found. The number of organs involved varied between 0 and 10 (median 3). The number of involved organs was not dependent on the disease extent at the time of diagnosis and on the type of treatment.


Subject(s)
Carcinoma, Small Cell/pathology , Lung Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Autopsy , Carcinoma, Small Cell/therapy , Combined Modality Therapy , Female , Humans , Lung Neoplasms/therapy , Male , Middle Aged
4.
Arch Gynecol Obstet ; 258(4): 171-80, 1996.
Article in English | MEDLINE | ID: mdl-8844134

ABSTRACT

Records of 42 patients with a diagnosis of uterine sarcoma treated between 1974 and 1995 at the Department of Oncology and Radiotherapy, Medical University of Gdansk have been reviewed. There were 15 cases of leiomyosarcoma, 14 cases of carcinosarcoma (malignant mixed mesodermal tumor) and 13 cases of endometrial stromal sarcoma. There were 24 FIGO stage I patients, 3 stage II patients, 7 stage III patients and 8 stage IV patients. Thirty seven patients had previously been operated on, of whom 33 had undergone total abdominal hysterectomy and bilateral salpingoophorectomy. Adjuvant postoperative treatment was administered in 19 patients and included radiotherapy in 16 patients, chemotherapy in two and chemotherapy and irradiation in one. Out of 31 radically operated patients, 19 (61%) had recurrences, within 2-42 months of primary treatment (median 10 months); nine patients had distant metasases, six patients had local recurrence and four had both local and distant failure. Treatment failure occurred in seven out of 14 patients who received adjuvant radiotherapy and in 12 out of 17 treated without irradiation. Median survival time in both groups was 26 months. The survival for the whole series ranged from 2 months to 19+ years (median 26 months) and was not related to tumor type. Two and five year actuarial survival rates were 54% and 30%, respectively.


Subject(s)
Sarcoma/epidemiology , Uterine Neoplasms/epidemiology , Adult , Aged , Carcinosarcoma/epidemiology , Carcinosarcoma/therapy , Combined Modality Therapy , Endometrial Neoplasms/epidemiology , Endometrial Neoplasms/therapy , Female , Humans , Leiomyosarcoma/epidemiology , Leiomyosarcoma/therapy , Middle Aged , Neoplasm Metastasis , Neoplasm Recurrence, Local , Sarcoma/therapy , Survival Rate , Uterine Neoplasms/therapy
5.
Ginekol Pol ; 66(8): 480-3, 1995 Aug.
Article in Polish | MEDLINE | ID: mdl-8675075

ABSTRACT

Approximately 2-3% of all breast cancers coincide with pregnancy or lactation and this tumour affects one to four out of 10000 pregnant women. Breast cancer associated with pregnancy (BCAP) has generally been believed to have a particularly grim prognosis. Several recent studies suggest however, that survival in BCAP does not substantially differ from that of non-pregnant, age and stage matched patients. BCAP may managed with standard methods. Surgery should be considered in all patients deemed to be operable. Therapeutic abortion does not need to be routinely performed, unless adjuvant chemotherapy or radiotherapy is to be applied or the patient necessitates systemic therapy for advanced disease. Prophylactic ovarian ablation does not influence significantly the course of BCAP and should be undertaken only in case of progressive or recurrent disease.


Subject(s)
Breast Neoplasms/therapy , Pregnancy Complications, Neoplastic/therapy , Abortion, Therapeutic , Breast Neoplasms/diagnosis , Breast Neoplasms/mortality , Female , Humans , Pregnancy , Pregnancy Complications, Neoplastic/diagnosis , Pregnancy Complications, Neoplastic/mortality , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...